Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tela Bio Inc (NQ: TELA ) 2.480 -0.140 (-5.34%) Streaming Delayed Price Updated: 1:44 PM EDT, Oct 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Tela Bio Inc < Previous 1 2 Next > TELA Bio Reports Second Quarter 2024 Financial Results and Reiterates Full Year 2024 Revenue Guidance August 12, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 09, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Participate in the Canaccord Genuity 44th Annual Growth Conference July 25, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Announce Second Quarter 2024 Financial Results July 22, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Appoints Jeffrey Blizard to its Board of Directors June 04, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Appoints Greg Firestone as Chief Commercial Officer May 20, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 10, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Reports First Quarter 2024 Financial Results May 09, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Announce First Quarter 2024 Financial Results April 25, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Procedures April 15, 2024 Targets the more than 665,000 inguinal hernia procedures performed annually in the United States (U.S.) From TELA Bio, Inc. Via GlobeNewswire TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategy April 08, 2024 Howard N. Langstein, MD, FACS joins innovative MedTech company to leverage his vast experience to help other surgeons optimize clinical outcomes in plastic and reconstructive surgery From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces U.S. Commercial Launch of LIQUIFIX™ – the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgery March 21, 2024 Strong and secure, LIQUIFIX is the first approved adhesive-based product to affix mesh without penetrating patient tissue From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces Sale of Distribution Rights for Wound Care Product to MIMEDX March 20, 2024 TELA Bio to receive at least $8 million and up to $12 million in total consideration From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Announce Fourth Quarter and Full Year 2023 Financial Results February 29, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 23, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 19, 2024 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 15, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Take Part in Connecting the Dots December 05, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Participate in Piper Sandler’s 35th Annual Healthcare Conference November 16, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 10, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Reports Third Quarter 2023 Financial Results November 09, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Announce Third Quarter 2023 Financial Results October 26, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Participate in the Gilmartin Group Emerging Growth Company Showcase September 18, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces U.S. Commercial Launch of OviTex® PRS Long-Term Resorbable for Plastic and Reconstructive Surgery August 16, 2023 New addition expands reconstruction options for surgeons and patients From TELA Bio, Inc. Via GlobeNewswire TELA Bio Reports Second Quarter 2023 Financial Results August 09, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) August 04, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Announce Second Quarter 2023 Financial Results and Confirms Participation in the Canaccord Genuity 43rd Annual Growth Conference July 26, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio to Participate in the Jefferies Global Healthcare Conference May 25, 2023 From TELA Bio, Inc. Via GlobeNewswire TELA Bio Invests in Surgeon Training and Education with Upcoming Cadaver Lab May 19, 2023 Company prioritizes education with a variety of in-person and virtual training programs From TELA Bio, Inc. Via GlobeNewswire TELA Bio Reports First Quarter 2023 Financial Results May 11, 2023 From TELA Bio, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.